Clinical study of esketamine in preventing adverse reactions of carboprost tromethamine during cesarean section

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054985

Enrollment

Unknown

Registered

2021-12-30

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Esketamine group:In the esketamine group, esketamine was given intravenously at a dose of 0.5 mg/kg

Control group:Normal saline

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. For women who are planning to undergo cesarean section, the American Society of Anesthesiologists (ASA) anesthesia grades I-II; 2. Aged 20-40 years; 3. Gestational age >= 37 weeks; 4. Intraoperative use of carboprost tromethamine; 5. Participation in this researcher is voluntary, and all signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications of combined spinal-epidural anesthesia; 2. Those who cannot accept cesarean section due to problems with the heart, lungs and other organs; 3. Patients with anesthesia diffusion level lower than T4; 4. Have perinatal diseases such as gestational hypertension and gestational diabetes; 5. Allergic to carboprost tromethamine and ropivacaine; 6. There are high-risk bleeding factors such as cephalopathy and polyhydramnios.

Design outcomes

Primary

Measure	Time frame
Heart rate;Respiratory rate;Oxygen saturation;Mean arterial pressure;Arterial oxygen partial pressure;	—

Countries

China

Contacts

Public ContactAn Shizhi

anshizhi73@sina.com+86 18053153231

Outcome results